Department of Neurology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.
Department of Medical Genetics, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
Front Immunol. 2022 Feb 10;13:821746. doi: 10.3389/fimmu.2022.821746. eCollection 2022.
Low free triiodothyronine (FT3) is usually associated with worse functional outcome in critical illness; however, the information on thyroid dysfunction and autoimmune encephalitis (AE) is limited. This study aims to evaluate the clinical prognostic value of thyroid function and low-T3 syndrome in patients with multiple subtypes of AE.
In this retrospective study, we identified the hospital records of 319 candidate patients with AE admitted between January 2016 and December 2020. We then extracted the clinical features and outcomes. Modified Rankin scale (mRS) scores were used to evaluate the patients' neurological function. The serum levels of FT3, free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were measured upon admission. Normal thyroid stimulating hormone level with FT3 below the lower limit of the reference interval (2.63 nmol/L) was defined as low-T3 syndrome.
A total of 237 AE cases remained after screening. Among these, 57.81% (137/237) were men and the average age at onset was 41 y (interquartile range, 12-61 y). We found that 83.54% (198/237) of the patients had a good prognosis, and 16.46% (39/237) had a poor prognosis. Abnormal thyroid function was observed in 30.80% of these patients, with a relatively greater prevalence in the group with a poor prognosis ( < 0.001). The serum FT3 levels in the poor-prognosis group were significantly lower than those in the good-prognosis group ( < 0.001). Low-T3 syndrome occurred in 15.19% of AE cases and was more frequent in patients with poor prognosis (p < 0.001).
Abnormal thyroid function in AE is frequent, and serum FT3 levels in patients with poor prognosis are significantly lower than in those with good prognosis. Low-T3 syndrome could be a potential candidate for predicting the prognosis of AE following future research.
游离三碘甲状腺原氨酸(FT3)水平降低通常与危重病患者的预后不良有关,但甲状腺功能障碍与自身免疫性脑炎(AE)的相关信息有限。本研究旨在评估多种 AE 亚型患者的甲状腺功能和低 T3 综合征的临床预后价值。
在这项回顾性研究中,我们筛选了 2016 年 1 月至 2020 年 12 月期间收治的 319 例 AE 候选患者的住院记录。我们提取了临床特征和结局。改良 Rankin 量表(mRS)评分用于评估患者的神经功能。入院时测量 FT3、游离甲状腺素(FT4)和促甲状腺激素(TSH)的血清水平。正常 TSH 水平但 FT3 低于参考区间下限(2.63 nmol/L)定义为低 T3 综合征。
筛选后共纳入 237 例 AE 病例。其中,57.81%(137/237)为男性,发病平均年龄为 41 岁(四分位距 12-61 岁)。我们发现,83.54%(198/237)的患者预后良好,16.46%(39/237)预后不良。这些患者中,30.80%存在甲状腺功能异常,预后不良组的发生率较高(<0.001)。预后不良组的血清 FT3 水平明显低于预后良好组(<0.001)。AE 病例中低 T3 综合征发生率为 15.19%,在预后不良患者中更为常见(p<0.001)。
AE 中甲状腺功能异常常见,预后不良患者的血清 FT3 水平明显低于预后良好患者。低 T3 综合征可能是未来研究预测 AE 预后的潜在候选指标。